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Abstract 
Background: While it has long been recognized that smooth muscle Na/K ATPase (NKA) 
modulates vascular tone and blood pressure (BP), the role of its accessory protein 
phopholemman (PLM) has not been characterized. The aim of this study was to test the 
hypothesis that PLM phosphorylation regulates vascular tone in vitro and this mechanism plays 
an important role in modulation of vascular function and BP in experimental models in vivo and 
in man. 
Methods: Mouse studies: PLM knock-in mice (PLM3SA), in which PLM is rendered 
unphosphorylatable, were used to assess the role of PLM phosphorylation in vitro in aortic and 
mesenteric vessels using wire myography and membrane potential measurements. In vivo BP and 
regional blood flow were assessed using Doppler flow and telemetry in young (14-16 weeks) and 
old (57-60 weeks) wild-type (WT) and transgenic mice. Human studies: We searched human 
genomic databases for mutations in PLM in the region of the phosphorylation sites and 
performed analyses within two human data cohorts (UK Biobank and GoDARTS) to assess the 
impact of an identified SNP on BP. This SNP was expressed in HEK cells and its effect on PLM 
phosphorylation determined using Western Blotting.  
Results: PLM phosphorylation at Ser63 and Ser68 limited vascular constriction in response to 
phenylephrine. This effect was blocked by ouabain. Prevention of PLM phosphorylation in the 
PLM3SA mouse profoundly enhanced vascular responses to PE both in vitro and in vivo. In 
ageing WT mice PLM was hypophosphorylated and this correlated with the development of 
ageing-induced essential hypertension. In man we identified a non-synonymous coding variant, 
single nucleotide polymorphism rs61753924, which causes the substitution R70C in PLM. In 
HEK cells the R70C mutation prevented PLM phosphorylation at Ser68. This variant’s rare 
allele is significantly associated with increased BP in middle-aged men.  
Conclusions: These studies demonstrate the importance of PLM phosphorylation in the 
regulation of vascular tone and BP and suggest a novel mechanism, and therapeutic target, for 
ageing-induced essential hypertension in man. 
Key Words: Na/K ATPase, phospholemman, vascular smooth muscle, vascular tone, 
hypertension, blood pressure 
Non-standard Abbreviations and Acronyms 
AI Augmentation Index 
BP blood pressure 
BRG Baroreceptor Gain 
CTS endogenous cardiotonic steroids 
GoDARTS Genetics of Diabetes Audit and Research in Tayside - biomedical database 
HRV Heart Rate Variability 
L-NAME L-NG-Nitro arginine methyl ester
Na/K ATPase sodium-potassium ATPase
NKA sodium-potassium ATPase
PE phenylephrine
PLM phospholemman (FXYD1)
PLM3SA phospholemman (FXYD1) in which the 3 phosphorylation sites on serines 63,
68 amd 69 are mutated to alanines
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UK Biobank UK Biobank - large-scale biomedical database 
VSM vascular smooth muscle 
VSMC vascular smooth muscle cell 
 
Clinical Perspective  
 
What is new? 
• Despite many previous studies implicating smooth muscle Na/K ATPase and endogenous 
cardiotonic steroids in hypertension, this is the first study demonstrating a role for its 
principle regulatory accessory protein phospholemman. 
• Phosphorylation of phospholemman profoundly influences vascular tone and blood 
pressure regulation in mice and its hypophosphorylation is associated with ageing-
induced essential hypertension.    
• In man, a single nucleotide polymorphism was identified in phospholemman exon 10 that 
results in an R70C mutation that in vitro leads to phospholemman hypophosphorylation 
and, in two human cohorts (UK Biobank and GoDARTS), is associated with a significant 
elevation of blood pressure in middle-aged men. 
 
What are the clinical implications? 
• Interventions that prevent PLM dephosphorylation and Na/K ATPase down-regulation 
may provide new therapeutic approaches to treatment of essential hypertension. 
• Existing interventions that prevent down-regulation of signalling pathways that terminate 
in PLM phosphorylation (for example beta blockers) may in part exert their beneficial 
antihypertensive effect through this mechanism. 
• The age and sex-dependence of these observations needs further investigation.
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Introduction 
The Na/K ATPase is ubiquitously expressed and maintains the Na and K trans-membrane 
gradients essential for a plethora of cell functions including electrical excitability, secondary 
active transport and cell signaling.1-3 
In vascular smooth muscle cells (VSMCs) the Na/K ATPase (specifically the 2 
isoform) plays an important role in modulating VSMC tone and blood pressure (BP).1,2,4-7 The 
hypertensive effects of Na/K pump inhibition with both exogenous and endogenous cardiotonic 
steroids (CTS) have long been recognized.8-10 Agents that stimulate the pump are hypotensive, 
while agents that inhibit the pump (and specifically the 2 subunit in VSM) are 
hypertensive.8,9,11 Endogenous CTS, for example, play a role in setting BP12 and exogenous 
ouabain completely blocks classical acetylcholine-induced NO-mediated vasodilation13 and 
substantially blocks reactive hyperaemia14 - suggesting that Na/K ATPase activity not only 
influences vascular contractility but is also central to the action of endogenous vasodilators.4,15-19 
Despite overwhelming evidence for a role of the Na/K ATPase in regulation of smooth 
muscle tone and BP, surprising little is known about the role of phospholemman (PLM), the 
muscle-specific regulator of Na/K ATPase, in modulating BP and even less is known about its 
possible contribution to hypertension. PLM (FXYD1) is a member of the FXYD family of Na/K 
ATPase modulatory proteins and in cardiac muscle links cellular signaling pathways 
(specifically PKC and PKA) to Na/K pump activation.20 In heart, phosphorylation of PLM 
disinhibits the Na/K ATPase by lowering its Km for Na and by increasing Vmax and hence 
increases Na efflux in response to hormonal stimulation and heart rate elevation.21-23  
While PLM is expressed in VSM, its role in regulating Na/K ATPase in this tissue has 
not been established and the limited literature is incomplete and contradictory.24,25,26 Thus, while 
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there is limited evidence that PLM may regulate Na/K ATPase in VSM, the physiological 
relevance of this is far from certain and its role in the control of BP has yet to be demonstrated. 
The primary aim of this study was, therefore, to test the hypothesis that PLM phosphorylation 
regulates vascular tone in vitro and this mechanism plays an important role in modulation of 
vascular function and BP in vivo. 
 
Methods 
An expanded methods section is available in the Data Supplement. The authors declare that all 
supporting data are available within the article and online Data Supplement or are are available 
from the corresponding author upon reasonable request. Access to source patient datasets is 
available to suitably qualified researchers through UKBB (https://www.ukbiobank.ac.uk) and 
GoDARTS (https://godarts.org). 
Animals and PLM3SA mice 
All experiments were performed in accordance with the Guidance on the Operation of Animals 
(Scientific Procedures) Act, 1986 (UK), the Directive of the European Parliament (2010/63/EU) 
and received approval by King’s College London Ethics Review Board. Male PLM3SA knock-in 
mice or their WT littermates (13-16 weeks of age (young) or 56-60 weeks of age (old)), were 
used in the majority of studies. A small number of studies used male Wistar rats (250g) (Charles 
River, UK). 
Myography 
Vascular rings were isolated from thoracic aortae of WT and PLM3SA mice, or rats, mounted in a 
tension myograph (Danish Myo Technology), optimally stretched, endothelial integrity tested 
(with acetylcholine) and concentration-response curves to PE and the thromboxane A2 mimetic 
 
D
ow
nloaded from
 http://ahajournals.org by on D
ecem
ber 18, 2020
10.1161/CIRCULATIONAHA.119.040557 
6 
U46619 constructed in the presence or absence of ouabain. Changes in isometric tension were 
sampled and recorded at 100Hz using a PowerLab and LabChart software (AD Instruments, New 
Zealand).  
In vivo hemodynamic assessment in mice 
Central arterial BP was measured in anesthetized mice via a pressure tipped catheter (1.2F, 
Transonic) inserted retrogradely into the ascending aorta via the right common carotid artery. 
The left jugular vein was cannulated for PE infusion. Surface ECG was continuously recorded. 
Augmentation index (AI) was calculated as previously described.27 In separate experiments, non-
invasive laser Doppler imaging (MoorLDI2 model; Moor Instruments Inc., Wilmington, USA) 
was used to assess hind-limb blood flow. Continuous hemodynamic measurements in conscious 
mice were performed by telemetry as described previously.28 Cardiac structure and function were 
assessed by 2D echocardiography.29 
Immunoblotting 
Thoracic aortae or mesenteric vessels were harvested from PLM3SA and WT mice, cleaned of fat 
and connective tissue, cut into 3-4 pieces and incubated at 37oC in gassed Krebs solution or 
Krebs plus PE (10µmol/L), U46619 (1µmol/L) or spNONO (100µmol/L). The tissue was snap 
frozen and stored at -80oC. Tissue homogenates (4%w/v) were size-fractionated on SDS-PAGE 
gels (10-15%) and processed for Western bloting as previously described.29 Alpha smooth 
muscle actin was used as a loading control. Signals from PLM3SA samples or treated WT samples 
were normalized to signals from control WT samples on the same gels or, for PLM 
phosphorylation, to total PLM. Details of antibodies, procedures and quantification can be found 
in the Data Supplement. 
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Membrane potential measurements 
Membrane potential was measured in 2mm segments of third-order mesenteric arteries mounted 
in a Mulvany-Halpern wire myograph (model 400A, Danish Myo Technology, Denmark) using 
sharp glass microelectrodes backfilled with 2mol/L KCl (tip resistances ~100MΩ). Tension was 
simultaneously recorded.30,31  
Genomic and phenotypic screening in patient populations 
We searched human genomic databases for mutations in PLM in the region of the 
phosphorylation sites. rs61753924 is a single nucleotide polymorphism (SNP) at 35,633,635 base 
pairs position (build hg19/37) on chromosome 19, in PLM exon 10, a C to T transition in 
position 1 of the codon encoding arginine 70 that generates a non-synonymous variant with the 
amino acid substitution R70C. In order to assess the impact of this SNP on BP, we analysed this 
SNP within two different human cohorts: UK Biobank (UKBB)32 and Genetics Of Diabetes 
Audit and Research in Tayside (GoDARTS).33,34 Details of the cohorts and the analysis can be 
found in the Data Supplement.  
The human data base analysis was been conducted using the UK Biobank Resource under 
application number 236. The genetic and phenotypic patient cohort data are available upon 
application to UK Biobank (https://www.ukbiobank.ac.uk) and GoDARTS (https://godarts.org). 
The UKBB study has approval from the North West Multi-Centre Research Ethics Committee. 
Any participants from UKBB or GoDARTS who withdrew consent have been removed from our 
analysis. 
Statistics 
Data are shown as means±standard error of the mean (SEM). Details of the analyses used can be 
found in the Data Supplement.  
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Results  
Prevention of PLM phosphorylation potentiates phenylephrine-induced vasoconstriction 
Figure 1(A) shows the dose-dependent constriction of isolated aortic rings to phenylephrine (PE) 
was potentiated in tissues isolated from PLM3SA mice.  The response of PLM3SA tissue was 
unaffected by ouabain but inhibition of Na/K ATPase in WT tissue rendered the WT hyper-
responsive to PE and similar to PLM3SA (Figure 2(B)).  
While PE-induced constriction was profoundly different between genotypes, and this 
difference was Na/K ATPase dependent, no differences were seen between genotypes in 
response to U46619 (Figure 1(C)). While U46619 interestingly also induced PLM 
phosphorylation at Sers63 and 68 (Figure 1(F)), this did not limit maximal constriction in WT 
aortae suggesting that, unlike PE-induced constriction, high concentrations of U46619 (0.1-
30µmol/L) mediate their constrictor effects via cellular mechanisms that are largely unaffected 
by PLM phosphorylation and Na/K ATPase activity. This is unsurprising as at these 
concentrations U46619 has been shown to potently inhibit the Na/K ATPase.35 
In parallel experiments, Western blot analysis (Figure 1(D-F)) showed that PE 
(10µmol/L) and U46619 (1µMmol/L) induced substantial PLM phosphorylation at Ser63 (PE) 
and Ser63 and Ser68 (U46619) in WT aortae. Expression of PLM, and both 1 and 2 subunits 
of the Na/K ATPase in aortic smooth muscle, were unaffected by genotype (see Figure I in the 
Supplement).  
A similar disparity between the role of Na/K ATPase in mediating the constrictor effects 
of PE and U46619 was also seen in rat aorta (see Figure II in the Supplement). At concentrations 
of U46619 below 30nmol/L there is a small ouabain-sensitive component (see Figure II(B) in the 
Supplement). Interestingly, U46619 induces PLM phosphorylation (see Figure 1(D,F)) which, 
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because of its concomitant Na/K ATPase inhibition, is largely without effect. This PLM 
phosphorylation is likely to reflect our previous observation that interventions raising cytosolic 
Ca will increase PLM phosphorylation by activating Ca-dependent PKCs.22 This may account 
for the small effect of ouabain on constriction in rat aorta at submaximal U46619 concentrations 
(i.e. below 30nmol/L) where the Na/K pump may still not be fully inhibited by U46619. 
On the basis of these experiments, we conclude that 1 adrenoceptor stimulation 
activates signaling pathways leading to phosphorylation of phospholemman at Ser63 
(presumably through a PKC dependent mechanism)36 and Na/K ATPase activation. In WT 
tissue, this exerts a ouabain-sensitive ‘relaxing’ effect which limits the overall constrictor effect 
of PE. When PLM phosphorylation is prevented in PLM3SA tissue, or when the Na/K ATPase is 
inhibited ouabain (or U46619), this ‘relaxing’ effect is lost and constriction is potentiated. 
The PLM-dependent limitation of PE-induced constriction in WT aortae is partially 
blocked by L-NAME 
Previous studies have shown that endothelially-derived factors modulate vascular responses to 
α1-adrenergic agonists via Na/K ATPase-dependent mechanisms.4,15-18,37 Furthermore, we have 
previously demonstrated that NO exerts PLM-dependent modulation of Na/K pump in cardiac 
tissue.38 We therefore hypothesized that at least part of the mechanism limiting PE-induced 
constriction in WT aortae may be NO-dependent. Figure III(A) in the Supplement shows the 
enhanced response of PLM3SA tissues to PE (cf WT) (as in Figure 1(A)). Subsequent NOS 
inhibition with L-NAME (300μmol/L) increased the dose-dependent contractile response to PE 
in both genotypes but the relative potentiation was more profound in WT mice than PLM3SA 
(Figure III in the Supplement). As a result of this potentiation, the difference in contractile 
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responses between genotypes after NOS inhibition was substantially reduced but still statistically 
significant (see Figure III(B) in the Supplement).  
These data suggest that in WT aortae, the ouabain-sensitive mechanism limiting PE-
induced constriction has two components – a NOS-dependent component (blocked by L-NAME) 
and a NOS-independent component (which persists in L-NAME). 
Aortic rings from WT mice are more sensitive to an NO donor  
To further investigate the role of PLM phosphorylation in NO-dependent regulation of the Na/K 
pump, in the next series of experiments we compared NO-dependent relaxation of aortic rings 
from both genotypes pre-constricted with a low concentration of U46619. The U46619 
concentration used in these experiments was 40nmol/L as at this concentration there is still a 
ouabain-sensitive modulation of constriction (see Figure 2(B)) while, at higher concentrations, 
U46619 is reported to directly inhibit Na/K ATPase.35 Initial tension after treatment with 
U46619 was the same across genotypes but spNONO-induced relaxation curves were left-shifted 
in aortic rings from WT mice, which reflects higher sensitivity of this genotype to NO (Figure 
IV(A) in the Supplement). Interestingly, pretreatment with ouabain (100μmol/L) profoundly 
limited the maximal relaxation response to NO and completely abolished the shift in the Km for 
spNONO between genotypes (Figure IV(B)) in the Supplement). These results demonstrate that 
(i) PLM-dependent Na/K pump activation is one of the mechanisms involved in NO-dependent 
relaxation, (ii) Na pump-independent mechanisms are not different between genotypes and (iii) 
PLM phosphorylation facilitates NO-dependent relaxation of WT aortic rings. Further evidence 
for a role of PLM phosphorylation in NO-dependent relaxation was seen in immunoblot 
experiments. Treatment of isolated aortic segments from WT mice with spNONO (100 µmol/L) 
time-dependently increased PLM phosphorylation (Figure IV(C,D,E) in the Supplement).  
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Thus, these in vitro experiments show that PLM phosphorylation and consequent Na/K 
ATPase activation both limits the contractile response to PE and enhances NO-dependent 
relaxation. Our next aim was to test whether such in vitro observations made in aortic rings are 
also seen in vivo and to establish whether PLM phosphorylation therefore plays a role in 
regulating vascular tone and BP? 
Vascular constriction in response to PE is profoundly enhanced in PLM3SA mice in vivo 
We measured augmentation index (AI) in anesthetized mice as an index of aortic stiffness/tone in 
vivo (Figure 2(A)). AI was measured in WT and PLM3SA mice at baseline and during PE infusion 
(iv, 10-300 μg/kg). Baseline AI was not different between genotypes, but PE treatment induced a 
dose-dependent elevation of AI in both genotypes. Furthermore, the increase in AI in response to 
PE was significantly enhanced in PLM3SA compared to WT mice (Figure 2(A)).  
PE-induced differences in AI could reflect differences in cardiac contractility, vascular 
stiffness, or both. To determine the contribution of any genotype-specific cardiac response to PE 
infusion, in separate experiments isolated hearts were treated with PE (Figure V(C) in the 
Supplement). PE modestly increased contractility of both WT and PLM3SA hearts to an identical 
extent. We conclude that the greater PE-induced elevation of AI in PLM3SA mice reflects 
enhanced vascular contractility in this model. 
In order to establish whether this enhanced vasocontractile response to PE in the PLM3SA 
mice is unique to aorta (or is a general feature of other vascular beds), blood flow in response to 
PE bolus injection was measured in hind-limb. Non-invasive laser Doppler hind-limb imaging in 
the two genotypes showed no differences in blood flow under baseline conditions (Figure 2(B-
D)). However, acute bolus PE infusion (iv, 30-300μg/kg) induced a more profound reduction of 
blood flow in PLM3SA mice than in WT littermates (Figure 2(B-D)) at all PE concentrations. 
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These data are consistent with the observation in Figure 2(A) of an enhanced constrictor 
response in aorta (AI) and augmented vascular contractility in PLM mutant mice in response to 
PE treatment in vivo.  
BP changes in PLM3SA mice: changes in baroreceptor gain and autonomic function 
Baseline BP was the same in conscious and anesthetized mice of both genotypes (Figure 3(A), 
and Figure VI(A) in the Supplement). Given the profoundly enhanced constrictor response of 
PLM3SA mouse to PE both in vitro and in vivo, surprisingly, PE infusion (iv, 10-300 μg/kg) 
induced identical dose-dependent pressor responses in WT and PLM3SA mice (Figure 3(A)). This 
appears to be explained by differences between genotypes in their baroreceptor function. Figure 
3(B) shows that the pressure-induced bradycardia was far more profound in PLM3SA than WT 
mice. Baroreceptor sensitivity can be estimated by plotting the change in heart rate (RR interval) 
as a function of change in BP (Figure 3(C). From this figure it is clear that the Baroreceptor Gain 
(BRG), as measured by the slope of this relationship, is almost 3 times higher in PLM3SA 
(1.42±0.11ms.mmHg-1) than WT mice (0.5±0.07ms.mmHg-1). This baroreceptor adaptation 
clearly allows the PLM3SA mouse to maintain normal BPs at rest, and over a range of pressor 
interventions, despite hyper-contractile vascular smooth muscle. Figure VI(B,C) in the 
Supplement also shows that these changes in BRG allow the PLM3SA mice to maintain 
comparable changes in systolic BP in response to acute environmental stress by limiting heart 
rate changes. Further evidence for autonomic adaptation in these mice is shown in the heart rate 
variability (HRV) analysis in Figure 3(D) and autonomic balance (Figure VI(D) in the 
Supplement). PLM3SA mice show significantly reduced low to high frequency ratio (Figure 3(D)) 
consistent with a chronic adaptive reduced sympathetic dominance and altered autonomic 
balance (Figure VI(D) in the Supplement).  
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Membrane potential measurements in mesenteric vessels: role of electrogenic Na/K pump 
activation? 
The high input impedance of vascular smooth muscle means that small changes in electrogenic 
Na/K pump activity can exert large effects on membrane potential (Em) and hence constriction. 
We, therefore, hypothesized that the ouabain-sensitive differences in response to PE are 
mediated by changes in Em. Figure 4(A) shows that at rest Em of WT mesenteric resistance 
vessels was -55±1.0mV. Of this, about -8mV can be attributed to the outward current carried by 
Na/K ATPase as ouabain, in WT vessels, reduces Em to -47±0.8mV. In the PLM3SA mouse, Em 
was considerably depolarized at rest (-50±0.5mV) and Em was no longer sensitive to ouabain - 
suggesting that, at rest, in the PLM3SA mouse, the contribution of the electrogenic Na/K ATPase 
to membrane potential is minimal. In WT mesentery (as in aorta – Figure 1(D,E)) PLM was 
basally phosphorylated at Ser63 (Figure VII in the Supplement). However, unlike in aorta PE did 
not induce further PLM phosphorylation at either Ser63 or Ser68 (Figure VII in the Supplement). 
The ability of PE to induce PLM phosphorylation in aortic but not mesenteric vessels suggest 
that while the Na/K ATPase and PLM exert tonic effects on vascular tone and membrane 
potential, the ability for this to be modulated by PE may vary in different vascular beds. The 
inability of PE to induce PLM phosphorylation also explains the similar constrictor responses to 
PE seen in WT and 3SA mesenteric vessels (Figure VIII in the Supplement).  
Role of PLM de-phosphorylation in ageing-induced essential hypertension in mice  
Having demonstrated the importance of PLM phosphorylation in the regulation of vascular 
smooth muscle tone and BP in young mice, we investigated whether changes in PLM 
phosphorylation are associated with ageing-induced essential hypertension. Figure 5(A) shows 
the diurnal variation in mean arterial pressure (MAP) in young mice (14-16 weeks of age) and 
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old hypertensive mice (57-60 weeks of age). In aortae from young mice, PLM was significantly 
basally phosphorylated at all 3 serine residues (Figure 5(D,E)). However, in old hypertensive 
mice PLM was very substantially hypo-phosphorylated and over-expressed (Figure 5(D,E)). 
There were no significant differences in 1 or 2 Na/K ATPase subunit expression with age 
(Figure IX(A) in the Supplement) but the increase in PLM expression resulted in a significant 
relative excess of unphosphorylated PLM in old mice (Figure IX(B) in the Supplement). 
BP in young and old wild-type and PLM3SA mice is shown in Figure 5(B,C). While wild-
type mice show substantial ageing-induced hypertension both during the day and night, PLM3SA 
mice are completely protected against hypertension at rest (day) and very substantially protected 
against hypertension during activity (night). In old WT mice average MAP at rest (day) was 
+13mmHg higher than in young mice, this hypertension was completely prevented in PLM3SA 
mice. During activity (night) old WT mice showed a substantial ageing-induced hypertension 
(+18mmHg) which was substantially abrogated in the PLM3SA genotype (+10mmHg). The heart 
rate variability differences seen in young mice (Figure 3(D)) were still present in aged mice 
(Figure X in the Supplement). Not only were PLM3SA mice protected against ageing-induced 
hypertension but they also were protected against ageing-induced cardiac dysfunction (Figure 
5(F) and Figure XI in the Supplement).  
A homologous varient in a human population influences BP 
We identified a single nucleotide polymorphism (SNP) in PLM that generates an R70C amino 
acid substitution in PLM. We hypothesized that R70C is unlikely to influence phosphorylation at 
PLM Ser68 by PKA (consensus motif RRXS/T). PKC isoforms generally require positive 
charges in positions +3, +2, -2 and -3 (consensus RRXS/TXRR),39 so we hypothesised that 
phosphorylation by PKC at Ser68 (but not Ser63 and Thr69) may be perturbed (Figure 6(A)). We 
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also investigated the possibility that mutation R70C destroys the proposed endoplasmic 
reticulum retention motif (RRR) in PLM.40 In HEK cells, the R70C PLM mutation is not 
phosphorylated at Ser68 by PKC (Figure 6(B,C), and displays enhanced cell surface localisation 
and palmitoylation (Figure XII in the Supplement) while phosphorylation at the more remote 
Ser63 site by PKC was unaffected by the R70C mutation (Figure 6(D)). 
To assess the impact of this SNP, we analysed data from UKBB including a total of 
357,151 unrelated individuals of European ancestry, with 159,204 males and 197,947 females 
(Table I in the Supplement). In total, 7,114 individuals carried at least one copy of the rare T 
allele of the SNP rs61753924, with a Minor Allele Frequency (MAF) of 1% and no evidence of 
departure from Hardy Weinberg Equilibirum (p=0.33). At recruitment, mean age was 56.4yrs, 
mean systolic BP (SBP) was 140.5mmHg and mean diastolic BP (DBP) was 84.1mmHg, with 
50.2% of indivudals being hypertensive (SBP ≥ 140mmHg or DBP ≥ 90mmHg) and 17.2% 
reported to be taking BP lowering medication. 
Within UKBB this SNP is associated with BP in a sex-and age-dependent manner (Figure 
7). The rare T allele is significantly associated with increasing levels of both SBP (0.77mmHg, 
95% CI 0.14-1.4, p=0.017) and DBP (0.4mmHg, 95% CI 0.02-0.79, p=0.04) in males. However, 
there is no significant association with BP in either the overall sample (p=0.16 for SBP; p=0.11 
for DBP) or within females (p=0.85 for SBP; p=0.75 for DBP). Hence this suggests a sex-
specific association. Focusing on results within males, Figure 7(A) illustrates an age-dependent 
effect of this SNP, with the association being significant only in the age-stratified analyses for 
males aged 45-50 yrs and 50-55 yrs old. Indeed an initial age-stratified analysis comparing males 
aged ≤55 yrs old vs males aged >55 years old shows that the rare T allele is significantly 
associated with increasing levels of both SBP (1.2mmHg, 95% CI 0.30-2.11, p=8.89×10-3) and 
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DBP (0.79mmHg, 95% CI 0.18-1.4, p=0.01) in males under 55yrs old, but is not significantly 
associated with BP in males over 55yrs old (p=0.28 for SBP; p=0.48 for DBP). We therefore 
conclude that the SNP has strongest effect in middle-aged men, with the rare T allele 
significantly increasing both SBP (1.7mmHg, 95% CI 0.59-2.8, p=2.62×10-3) and DBP 
(1.02mmHg, 95% CI 0.29-1.74, p=5.96×10-3) in males aged 45-55yrs old (Figure 7(E)). 
In a similar analysis in the GoDARTS cohort (n=7,784) the proportion of individuals carrying 
the T allele was slightly higher at 3%, compared to UKBB although in Hardy-Weinberg 
equilibrium (p=0.7).   We replicated the findings from UKBB with the T allele showing 
significant association with SBP increased by 4.5mmHg, 95%CI 0.72-8.27 (P=0.02) only in 
middle-aged males aged of 40-65 years.   
 
Discussion  
These studies demonstrate the importance of phospholemman (PLM)-mediated regulation of 
vascular smooth muscle Na/K ATPase activity, membrane potential, tone and BP. PLM 
phosphorylation stimulates Na/K ATPase which limits agonist-induced vascular smooth muscle 
depolarisation and hence limits constriction (see Figure 8). The presence of a SNP that abolishes 
PLM phosphorylation at Ser68 by PKC is significantly associated with increased BP in middle-
aged men. Mutation of the phosphoregulatory sites on PLM in mice blocks this pathway and 
renders vascular smooth muscle hyper-responsive to phenylephrine. These PLM3SA mice show a 
chronic adaptation of their baroreceptor sensitivity which can maintain normal BP at rest in 
response to exogenous phenylephrine (or environmental stress) despite a profoundly enhanced 
peripheral vasoconstriction. The autonomic adaptations in these mice can prevent chronic 
essential hypertension induced by ageing. In aged wild-type mice the combination of increased 
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PLM expression and profound PLM hypo-phosphorylation is associated with hypertension which 
was largely abrogated by autonomic adaptations in PLM3SA mice. This raises the possibility that 
PLM and the prevention of its dephosphorylation and Na/K ATPase inhibition may provide a 
novel therapeutic target in ageing-induced essential hypertension. 
Mechanism of PLM-mediated modulation of vasoconstriction:  
A number of studies have shown that Na/K ATPase modulates vascular tone independent of 
changes in intracellular Na.3,41,42 We therefore propose that activation of vascular smooth muscle 
Na/K ATPase, and the PLM-mediated ouabain-sensitive relaxing effect, involves increased 
electrogenic Na/K pump current which hyperpolarizes the cell membrane or limits agonist-
induced depolarisation. Preventing PLM phosphorylation in PLM3SA mice profoundly 
depolarizes resting membrane potential in mesenteric arteries from -55±2mV (WT) to -50±1mV 
(PLM3SA). The steep current-voltage relationship of the L-type Ca channel window-current 
means that such a change in membrane potential can significantly increase steady-state Ca influx 
and hence increase vascular tone in 3SA vessels. In WT vessels, this ouabain-sensitive 5mV 
hyperpolarisation persisted across the entire range of depolarisations induced by PE. In these 
mesenteric vessels this hyperpolarisation was not further enhanced by a concentration-dependent 
PE-induced Na/K pump activation as PLM phosphorylation was not further increased by PE 
treatment (unlike in aorta).  
Differences in the role of PLM in U46619 and PE-induced constriction:  
Our data suggests that the constrictive effects of PE are limited by two factors – PLM 
phosphorylation activating the Na/K ATPase and (ii) endothelially derived NO release. Neither 
of these occur in U46619 constriction as the Na/K ATPase is already inhibited by U46619 and 
U46619 has been reported to inhibit rather than promote NO release from the endothelium.43,44 
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Role of nitric oxide (NO) in PLM modulation of relaxation:  
Figure IV in the Supplement also shows that nitric oxide (NO), as in cardiac muscle,38 can also 
induce PLM phosphorylation. Hence a component of classical NO-mediated relaxation is likely 
to involve the activation of Na/K ATPase via this mechanism. As PE also stimulates the 
generation of NO,37 it can therefore limit constriction through direct PKC-mediated 
phosphorylation of PLM and also via more classical NO-dependent downstream pathways which 
are PLM-independent.  
NOS inhibition significantly augmented dose-dependent constriction to PE in both 
genotypes (Figure III in the Supplement) demonstrating the presence of a PLM-independent 
effect of PE that antagonizes constriction. However, potentiation of constriction by L-NAME 
was most profound in the WT aortic segments (Figure III in the Supplement) suggesting that 
PLM phosphorylation plays a role in NO-dependent modulation of PE-induced constriction. 
Interestingly, even in the presence of L-NAME, aortic constriction to PE was higher in PLM3SA 
mice than in WT (Figure III in the Supplement) demonstrating that PE activates a complex array 
of NO-dependent/independent and PLM-dependent/independent mechanisms that antagonize 
PE-induced constriction.  
The assumption is that the 3SA mutation mediates its effects by influencing Na/K 
ATPase activity in vascular smooth muscle. However, the 3SA is a global knock-in under the 
control of the endogenous PLM promotor.  However, FXYD proteins are ubiquitous and it is 
likely that vascular endothelium will express its own FXYD protein which has yet to be 
identified. It seems unlikely that this will be FXYD1 (PLM) as all reports suggest that this is 
muscle-specific. We have failed to detect PLM in endothelial cell (HUVEC) cultures (data not 
shown). None of the other members of the FXYD family contain the cytoplasmic tail with the 
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regulatory phosphorylation site and so they could not be candidates for modulation by 
phosphorylation. Should aortic vascular endothelium express FXYD1 (PLM) then this could 
affect the Na gradient in endothelial cells and hence intracellular Ca and NOS-induced NO 
release.  
In vivo adaptations and control of blood pressure 
The role of PLM phosphorylation in the regulation of vascular tone was also confirmed in vivo. 
Augmentation Index (AI) is influenced by the velocity and amplitude of the aortic pressure wave 
reflection and is proportional to arterial stiffness.45-48 In PLM3SA mice, AI was similar to that in 
WT at baseline but the response to acute administration of PE was profoundly amplified in 
PLM3SA mice (Figure 2(A)). In addition, hind limb resistance vessels also show enhanced 
constriction in response to bolus infusion of PE in PLM3SA mice (Figure 2(B,C,D).  
Surprising, despite this profoundly enhanced vascular responsiveness, in vivo BP was not 
different between the genotypes even during PE infusion (Figure 3(A)). This lack of enhanced 
pressor response to PE despite a profound increase in both central and peripheral 
vasoconstriction is explained by an enhanced reflex bradycardia (Figure 3(B)). This is best 
demonstrated by the change in baroreflex gain in Figure 3(C). The PLM3SA mouse has a 
baroreflex sensitivity almost 3 times that of the wild-type mouse (1.42±0.11 vs 
0.5±0.07ms.mmHg-1). There also appears to be an autonomic compensation under baseline 
conditions that is reflected in reduced LF/HF Ratio (sympathetic dominance) of Heart Rate 
Variability (Figure 3(D)) measured in conscious telemetered mice. Pharmacological inhibition of 
sympathetic and parasympathetic activity revealed substantially lower activity in both limbs of 
the autonomic nervous system and lower intrinsic heart rate in PLM3SA mice (Figure VI(D) in the 
Supplement). New environment stress induced similar elevation of BP in both genotypes but 
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again the chronotropic response was limited in PLM3SA mice (Figure VI(B,C) in the 
Supplement). Thus, different autonomic control of heart rate, lower intrinsic pacemaker activity 
and higher baroreflex sensitivity appear to underlie adaptive mechanisms allowing PLM3SA mice 
to maintain normal arterial BP despite the absence of PLM-dependent modulation of vascular 
function.  
Phospholemman phosphorylation and ageing-induced essential hypertension 
Ageing in WT mice is associated with essential hypertension (Figure 5(A,C)) and a gradual 
increase in arterial stiffness.49 There is a profound age-related reduction of PLM phosphorylation 
at all PLM phosphorylation sites accompanied by increased PLM expression in aortic tissue 
(Figure 5(D,E)). This combination of increased PLM expression and profound 
dephosphorylation will inhibit Na/K ATPase. A reduction in Na/K ATPase activty may not only 
affect vascular tone, as decsribed in this study, but may also lead to chronic vascular 
remodelling.7 PLM3SA mice were very significantly protected against this ageing-induced 
hypertension and HRV analysis suggests that these old PLM3SA mice maintain their adaptive 
changes in autonomic function in a way that protects them against ageing-induced hypertension 
(Figure X in the Supplement).  
Our previous studies demonstrated that PLM3SA mice are more prone to cardiac 
hypertrophy and dysfunction in a banding model of heart failure.29 However, it is interesting to 
note that aged PLM3SA mice in this study show no cardiac hypertrophy, and reduced contractile 
dysfunction compared to aged WT littermates (Figure 5(F) and Figure XI in the Supplement). 
This suggests that the reduction in the trigger for hypertrophy (ie essential hypertension) in 
ageing PLM3SA mice can compensate for the previously shown vulnerability of these mice to 
pressure overload.  
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While it is tempting to suggest that the down-regulation of Na/K pump function in WT 
mice is causally associated with ageing-induced hypertension, and the protection afforded in the 
PLM3SA mouse suggests a causal role for PLM phosphorylation, it is also possible that the 
chronic down-regulation of sympathetic outflow in the PLM3SA mouse is akin to a life-time of 
beta blockade and the changes in WT PLM are merely co-incidental.  
Therapeutic potential of targeting the PLM/NKA regulatory axis in hypertension  
In humans, the R70C PLM mutation (rs61753924) has a significant impact on BP profiles. At 
middle age possession of the T allele is associated with both increased SBP and DBP levels. In 
particular, middle-aged male carriers have 1.7mmHg higher mean SBP. Within the general 
population, an effect of this size for a single SNP alone is substantial. The results of BP genetic 
association studies, considering the effect of all common variants (MAF≥1%) associated with 
BP, show that the maximum effect size for a single common variant is ~1.2mmHg for SBP, with 
the average effect size across all SBP-associated SNPs being ~0.3 mmHg.50 Furthermore, even 
the genetic risk score combining together the effects of all 901 independent BP-associated SNPs 
reported in 2018 shows an aggregated risk of only ~10mmHg difference in mean SBP when 
comparing individuals in the top vs bottom 20% of the genetic risk distribution. Of course, there 
is an increasing trend between the effect size of associated SNPs and their MAF, with only rare 
variants expected to have larger effects, and indeed this is a low-frequency SNP with MAF=1%, 
however even in recent BP genetic studies investigating rare variants, very few individual SNPs 
have still been identified with an effect size for SBP of >2mmHg.51 We note however, that due to 
the rare frequency of this SNP, and considering the highly polygenic nature of BP within the 
general human population, we do not claim any strong clinical impact for this SNP alone. 
Instead, it is only really genetic mutations for monogenic hypertension syndromes which are 
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expected to have larger, clinically meaningful effect sizes for single mutation variants.50,51 
Therefore we suggest that the large effect size of this SNP for increasing BP levels within 
middle-aged men demonstrates the importance of the PLM/Na/K ATPase regulatory pathway in 
the overall control of BP. PLM-mediated Na/K ATPase activation may offer therapeutic 
potential for poorly-managed essential hypertension.  
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Figure Legends   
Figure 1. Phospholemman (PLM) phosphorylation limits phenylephrine-induced 
vasoconstriction in wild-type (WT) isolated mouse aortic rings in a ouabain-sensitive 
manner. Mutation of PLM to prevent phosphorylation (3SA) enhances constriction. 
Constriction in response to the thromboxane A2 mimetic U46619, which also increases 
PLM phosphorylation, was unaffected by genotype. A: Mutation of PLM phosphorylation 
sites to prevent phosphorylation (3SA) markedly enhanced vasoconstriction (n=6 (WT) and n=5 
(3SA), #P<0.001 2-way ANOVA for Vmax comparison). B: The limitation of vasoconstriction in 
wild-type (WT) aortae was completely blocked by pretreatment with ouabain (300μmol/L) 
(n=5/group). C: Contractile response to the thromboxane A2 mimetic U46619 was unaffected by 
genotype (n=6 (WT) and n=7 (3SA)). D, E and F: In WT aortae both phenylephrine (10µmol/L) 
and U46619 (1 µmol/L) markedly increased PLM phosphorylation (n=6/group, *P<0.05, 
***P<0.001 unpaired t-test). 
 
Figure 2. In vivo measurements of aortic stiffness as assessed by augmentation index, and 
peripheral blood flow measured in anaethetized wild-type and PLM3SA (3SA) mice in 
response to phenylephrine. Phenylephrine (PE) was infused as a bolus injection via a left 
jugular vein catheter at the doses indicated. A: Aortic pressure measurements were made via a 
pressure tipped catheter (1.2F, Transonic) introduced into the ascending thoracic aorta via the 
right carotid artery. Augmentation Index was measured as the percentage increase in aortic 
pressure from the first inflection in the aortic pressure trace to the subsequent peak pressure (n=5 
for both groups). B-D: In separate experiments, peripheral blood flow was measured in the hind-
limb by laser Doppler in response to PE bolus infusion (n=5 (3SA) and n=6 (WT)). In Panels A, 
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B and C comparisons were made using 2-way ANOVA with Bonferroni correction and 
#P<0.001 for effect of both genotype and PE concentration and specifically *P<0.05, 
***P<0.001. 
 
Figure 3. In vivo measurements of Mean Arterial Pressure (MAP), heart rate, baroreceptor 
reflex gain and autonomic function in anaethetized wild-type and PLM3SA (3SA) mice in 
response to phenylephrine. Phenylephrine (PE) was infused as a bolus injection via a jugular 
vein catheter at the doses indicated. A: Mean Arterial Pressure measurements were made as 
described in Figure 2 and heart rate (B) was a calculated from the pressure trace. Baroreceptor 
reflex gain (BRG) was estimated by plotting the change in beat-beat interval (RR) as a function 
of change in MAP (MAP) in response PE infusion (C) with BRG estimated as the slope of this 
relationship (*P<0.05). The Low/High frequency component (Sympathetic dominance) of Heart 
Rate Variability (HRV) measured in conscious telemetered mice under control conditions is 
shown in Panel D. (Panels A-C, n= 5/group) and Panel D, n=11/group. In Panel B comparison 
were made using 2-way ANOVA with Bonferroni correction and #P<0.001 for effect of both 
genotype and PE concentration and specifically *P<0.05.  Difference in Panel D was tested using 
an un-paired t-test **P<0.005. 
 
Figure 4. Effect of phenylephrine (PE) on membrane potential measured in mesenteric 
vessels isolated from wild-type (WT) and PLM3SA (3SA) mice: A: Effect of ouabain 
(300µmoles/L) on basal membrane potential measured in WT and 3SA mesentery. Resting 
membrane potential was more hyperpolarized in WT than 3SA vessels – an effect which was lost 
when vessels were exposed to ouabain. Comparisons were made using 1-way ANOVA followed 
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by an un-paired t-test (*P<0.05). B: Phenylephrine (PE) induces an equivalent dose-dependent 
net depolarization in both 3SA and WT vessels with the WT vessels starting approximately 5mV 
more hyperpolarized. Comparisons were made using 2-way ANOVA with Bonferroni correction 
and #P<0.0001 for effect of both genotype and PE concentration and specifically *P<0.05 (n=4 
(WT) and n=6 (3SA)). 
 
Figure 5. Ageing-induced essential hypertension was associated with significant PLM hypo-
phosphorylation in wild-type mice. PLM3SA mice were substantially protected against both 
this ageing-induced hypertension and the associated cardiac hypertrophy and contractile 
dysfunction. A: Ageing-induced essential hypertension measured over 48 hours in telemetered 
young (14-16 weeks) and old (57-60 weeks) wild-type mice. B: In 3SA mice, the diurnal 
fluctuation of BP was similar to that in young WT mice but nocternal hypertension was 
significantly attenuated in 3SA mice. C: Average Mean Arterial Pressures (MAP) recorded in 
young and old mice during day and night-time by genotype. D and E: In WT mice PLM was 
substantially hypo-phosphorylated at serines 63, 68 and 69 in aortic tissue from old mice 
(n=6/group, *P<0.05). F: PLM3SA mice were also protected against ageing-induced cardiac 
contractile dysfunction (ejection fraction) (See also Figure XI in the Supplement). In Panels A 
and B comparisons were made using 2-way ANOVA with Bonferroni correction and #P<0.001 
for effect of both age and time and specifically *P<0.05. In Panels C and F comparison were 
made using 1-way ANOVA with Bonferroni correction and in Panel E unpaired t-test was used 
for comparison. n=10 (adult, WT), n=9 (old, WT), n=11 (adult, PLM3SA ), n=11 (old, PLM3SA), 
*P<0.05. **P<0.01. ***P<0.001. 
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Figure 6. The R70C mutation limits PKC but not PKA phosphorylation of PLM at Ser68 
but does not affect phosphorylation at the more remote Ser63. A: Position of the R70C 
mutation in human PLM. The PKC and PKA phosphorylation sites at Ser63, Ser68 and T69 are 
indicated. B: Phosphospecific immunoblots after activation of PKA or PKC in transfected WT 
and R70C HEK cells. C: and D: quantified PLM Ser68 and Ser63 phosphorylation respectively. 
In Panels C and D unpaired t-test was used for comparison (C: n=7/grp and D: n=3-5). *P<0.05; 
**P<0.005. All other comparisons between WT and R70C not significant. 
 
Figure 7. The R70C phospholemman mutation (rs61753924) is associated with an age- and 
sex-dependent effect on BP in two human cohorts - UK BioBank and GoDARTS. CC = 
comparitor (control) and CT and TT represent heterozygote and homozygote genotypes. Mean 
systolic and diastolic BPs, within 5-year age intervals, are shown in both cohorts. The T-allele 
was associated with a significant increase in both systolic and diastolic BP in males (A and B) 
but not females (C and D), and especially associated within middle-aged males (E and F). Panels 
A-D plot the mean BP estimates within each age-group and tests for significant differences 
between consecutive age groups, according to non-overlapping 95% Confidence Intervals. 
Panels E-F show the mean BP estimates within middle-aged subjects corresponding to results 
from the age-stratified linear regression analyses, testing for a significant difference in mean BP 
between CC vs CT/TT genotype groups. Sample sizes: UKBB: n=159,204 males (A), 197,947 
females (C), 44,995 middle-aged (45-55yrs) males and 58,194 middle-aged females (E).  
GoDarts: n=4,460 males (B), 3,324 females (D), 1,786 middle-aged (45-60yrs) males and 1,187 
middle-aged females (F). *P<0.05. 
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Figure 8. Proposed mechanisms by which phospholemman (PLM) phosphorylation and 
Na/K ATPase activation modulates vascular contractility: (1): Activation of cell surface 
receptors ie by phenylephrine or noradrenaline (NA) activates IP3 and protein kinase C (PKC). 
(2): This elevates cytosolic Ca through a combination of membrane depolarization and enhanced 
Ca entry (principally via voltage-gated channels) and cyclic sarcoplasmic reticulum (SR) Ca 
release leading to constriction. (3): PKC, whose activation is enhanced by elevation of cytosolic 
Ca, phosphorylates phospholemman (at either Ser63 or both Ser63 and Ser68). (4): 
Phosphorylated PLM dis-inhibits the Na/K ATPase (NKA) which generates an outward current 
limiting the depolarization of the cell membrane and hence limiting Ca influx through voltage-
gated channels and/or lowers cytoplasmic Na facilitating Ca efflux via Na/Ca exchange. This 
limits the rise in Ca in the cytosol and hence limits constriction. (5): The receptor-mediated rise 
in cytosolic Ca also passes to adjacent endothelial cells where it activates both nitric oxide 
synthase (NOS) and the release of EDHF. Nitric oxide (NO) diffuses to smooth muscle cells 
where it limits constriction by two pathways (i) via the canonical cGMP/PKG pathway (6) and 
(ii) via activation of a PLM/NKA-dependent pathway (7). EDHF release from endothelial cells 
may also limit depolarization possibly via activation of ouabain-sensitive NKA (8). Basal 
phosphorylation of PLM influences vascular tone via these mechanisms and, in the PLM3SA 
mouse, adaptive changes in baroreceptor gain and autonomic control maintain baseline resting 
BP despite enhanced vascular reactivity (9). In aged mice, and in humans expressing the R70C 
mutation, defects in this PLM/NKA mechanism contribute to hypertension. 
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